{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:50:47Z","timestamp":1785408647245,"version":"3.56.0"},"reference-count":38,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Neutropenia is an adverse event of systemic chemotherapy with various complications that affect patient management, quality of life, and could be fatal. The study was conducted to evaluate chemotherapy-induced neutropenia (CIN) in a Palestinian cohort of patients with solid malignancies. This article examines patient characteristics, risk factors for neutropenia severity, and neutropenia management patterns. The study included a total of 171 adult patients diagnosed with solid malignancies who were on their first chemotherapy regimens with no history of neutropenia. Data were collected retrospectively from patients\u2019 electronic medical records. Only patients who developed neutropenia during treatment were included in this study, and patients were classified into three groups of severity based on the absolute neutrophil count (ANC). Colon cancer and lung cancer were the most reported. Epirubicin, paclitaxel, cyclophosphamide, and doxorubicin were significantly associated with neutropenia severity, in addition to the number of chemotherapy cycles, stage at diagnosis, and certain comorbidities. Of the total patients, 32.5% reported substance use which was also significantly associated with severity. The majority of patients received primary granulocyte colony-stimulating factor (GCSF) prophylaxis. Sixty-nine percent of patients presented with febrile neutropenia. Hospitalization, antibiotics, antipyretics, and GCSF were utilized for management in most patients. Neutropenia severity was associated with the chemotherapy agents used, whereas the type of solid malignancy was not. Substance use represented a high burden among our cohort, and its association with severity could be further studied. Primary GCSF prophylaxis is critical, with patients not receiving it developing profound neutropenia (ANC &amp;lt;0.1 \u00d7 109) at higher rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>CIN causes high utilization of medical resources and disrupts treatment schedules. Factors possibly associated with severity include stage at diagnosis, number of chemotherapy cycles, select agents, and comorbidities. GCSF prophylaxis possibly decreases profound neutropenia rates. Palestinian patients with cancer have a high burden of substance use, possibly reflecting unmet needs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0770","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:11:46Z","timestamp":1782346306000},"page":"1714-1720","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemotherapy-Induced Neutropenia in Palestinian Patients with Solid Malignancies: Patient Characteristics, Severity Risk Factors, and Management Patterns"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5292-0712","authenticated-orcid":false,"given":"Natalie","family":"Khamashta","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04hym7e04","id-type":"ROR","asserted-by":"publisher"}],"name":"Al-Quds University 1 Faculty of Medicine, , Jerusalem, Palestine."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8646-3061","authenticated-orcid":false,"given":"Ahmad","family":"Dalal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04hym7e04","id-type":"ROR","asserted-by":"publisher"}],"name":"Al-Quds University 1 Faculty of Medicine, , Jerusalem, Palestine."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1925-0364","authenticated-orcid":false,"given":"Mo\u2019men","family":"Alashwas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04hym7e04","id-type":"ROR","asserted-by":"publisher"}],"name":"Al-Quds University 1 Faculty of Medicine, , Jerusalem, Palestine."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3398-5364","authenticated-orcid":false,"given":"Musab","family":"Hamdan","sequence":"additional","affiliation":[{"name":"2Department of Oncology, Palestine Medical Complex, Ramallah, Palestine."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9456-2762","authenticated-orcid":false,"given":"Fuad","family":"Al-Rimawi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04hym7e04","id-type":"ROR","asserted-by":"publisher"}],"name":"Al-Quds University 3 Chemistry Department, Faculty of Science and Technology, , Jerusalem, Palestine."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9001-4892","authenticated-orcid":false,"given":"Yousef","family":"Sahoury","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04hym7e04","id-type":"ROR","asserted-by":"publisher"}],"name":"Al-Quds University 4 Pharmacology and Physiology Department, Faculty of Medicine, , Jerusalem, Palestine."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"2026071706011081300_bib1","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","article-title":"Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026071706011081300_bib2","doi-asserted-by":"publisher","first-page":"e3240","DOI":"10.1097\/MD.0000000000003240","article-title":"Prognostic value of chemotherapy-induced neutropenia at the first cycle in invasive breast cancer","volume":"95","author":"Ma","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2026071706011081300_bib3","doi-asserted-by":"publisher","first-page":"e234881","DOI":"10.1001\/jamanetworkopen.2023.4881","article-title":"Neutropenic fever\u2013associated admissions among patients with solid tumors receiving chemotherapy during the COVID-19 pandemic","volume":"6","author":"Baus","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026071706011081300_bib4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1159\/000506109","article-title":"Febrile neutropenia in patients with solid tumors undergoing intravenous chemotherapy","volume":"43","author":"Moreira-Pinto","year":"2020","journal-title":"Oncol Res Treat"},{"key":"2026071706011081300_bib5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/01.JAA.0000000000000054","article-title":"Evaluation and management of febrile neutropenia in patients with cancer","volume":"37","author":"Cossey","year":"2024","journal-title":"JAAPA"},{"key":"2026071706011081300_bib6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","article-title":"Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed?","volume":"27","author":"Boccia","year":"2022","journal-title":"Oncologist"},{"key":"2026071706011081300_bib7","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s00520-017-3692-x","article-title":"Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population","volume":"25","author":"Kawatkar","year":"2017","journal-title":"Support Care Cancer"},{"key":"2026071706011081300_bib8","article-title":"Cancer in Palestine, West Bank, five -year cancer report 2017\u20132021, annual cancer report 2022","author":"The National Cancer Registry\/Palestinian Health Information Center","year":"2023"},{"key":"2026071706011081300_bib9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.71152\/ajms.v16i7.4594","article-title":"Chemotherapy-induced neutropenia and its determinants in patients with solid malignancies: a prospective observational study","volume":"16","author":"Whitney Joseph","year":"2025","journal-title":"Asian J Med Sci"},{"key":"2026071706011081300_bib10","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/annonc\/mdu203","article-title":"History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis","volume":"25","author":"Chao","year":"2014","journal-title":"Ann Oncol"},{"key":"2026071706011081300_bib11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00520-010-0840-y","article-title":"Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study","volume":"19","author":"Schwenkglenks","year":"2011","journal-title":"Support Care Cancer"},{"key":"2026071706011081300_bib12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.4143\/crt.2023.784","article-title":"Impact of patient sex on adverse events and unscheduled utilization of medical services in cancer patients undergoing adjuvant chemotherapy: a multicenter retrospective cohort study","volume":"56","author":"Choi","year":"2024","journal-title":"Cancer Res Treat"},{"key":"2026071706011081300_bib13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1365-2354.2009.01121.x","article-title":"Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours","volume":"19","author":"L\u00f3pez-Pousa","year":"2010","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"4 Suppl 2","key":"2026071706011081300_bib14","first-page":"18","article-title":"Greater risks of chemotherapy toxicity in elderly patients with cancer","volume":"1","author":"Repetto","year":"2003","journal-title":"J Support Oncol"},{"issue":"11 Suppl 11","key":"2026071706011081300_bib15","first-page":"27","article-title":"Myelosuppression and its consequences in elderly patients with cancer","volume":"17","author":"Balducci","year":"2003","journal-title":"Oncology (Williston Park)"},{"key":"2026071706011081300_bib16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","article-title":"Risk models for predicting chemotherapy-induced neutropenia","volume":"10","author":"Lyman","year":"2005","journal-title":"Oncologist"},{"key":"2026071706011081300_bib17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000355107","article-title":"Cigarette smoking and gemcitabine-induced neutropenia in advanced solid tumors","volume":"85","author":"O\u2019Malley","year":"2013","journal-title":"Oncology"},{"key":"2026071706011081300_bib18","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/annonc\/mdp008","article-title":"A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia","volume":"20","author":"Kanai","year":"2009","journal-title":"Ann Oncol"},{"key":"2026071706011081300_bib19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4172\/2153-2435.1000132","article-title":"Neutropenia onset, severity and their association with solid cancer diseases","volume":"2","author":"Hassan","year":"2011","journal-title":"Pharm Anal Acta"},{"key":"2026071706011081300_bib20","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1093\/annonc\/mdr520","article-title":"Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre","volume":"23","author":"Schelenz","year":"2012","journal-title":"Ann Oncol"},{"key":"2026071706011081300_bib21","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/cam4.200","article-title":"Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study","volume":"3","author":"Culakova","year":"2014","journal-title":"Cancer Med"},{"key":"2026071706011081300_bib22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.14740\/wjon1530","article-title":"Advanced stage is a risk for severe neutropenia in breast cancer patients undergoing neoadjuvant adriamycin\/cyclophosphamide\/docetaxel chemotherapy","volume":"13","author":"Moro","year":"2022","journal-title":"World J Oncol"},{"key":"2026071706011081300_bib23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lungcan.2020.01.004","article-title":"Predicting risk of chemotherapy-induced severe neutropenia: a pooled analysis in individual patients data with advanced lung cancer","volume":"141","author":"Cao","year":"2020","journal-title":"Lung Cancer"},{"key":"2026071706011081300_bib24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00520-010-0821-1","article-title":"Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer","volume":"19","author":"Hosmer","year":"2011","journal-title":"Support Care Cancer"},{"key":"2026071706011081300_bib25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3390\/ph14070681","article-title":"Comprehensive analysis of chemotherapeutic agents that induce infectious neutropenia","volume":"14","author":"Okunaka","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026071706011081300_bib26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.31557\/apjcc.2022.7.2.285-293","article-title":"Risk factors predicting chemotherapy-induced severe neutropenia and outcome in advanced stage non-small cell lung cancer: data from the limited resource in Thailand","volume":"7","author":"Neesanun","year":"2022","journal-title":"Asian Pac J Cancer Care"},{"key":"2026071706011081300_bib27","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood.V89.7.2303","article-title":"Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model","volume":"89","author":"Mac Manus","year":"1997","journal-title":"Blood"},{"key":"2026071706011081300_bib28","doi-asserted-by":"publisher","first-page":"e27163","DOI":"10.1097\/MD.0000000000027163","article-title":"Traditional herbal medicine combined with first-line platinum-based chemotherapy for advanced non-small-cell lung cancer: a PRISMA-compliant systematic review and meta-analysis","volume":"100","author":"Jin","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2026071706011081300_bib29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11096-019-00952-x","article-title":"The association between chemotherapy-induced febrile neutropenia and breast cancer subtype in Japanese patients","volume":"42","author":"Nomura","year":"2020","journal-title":"Int J Clin Pharm"},{"key":"2026071706011081300_bib30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.eururo.2016.06.041","article-title":"Docetaxel for metastatic hormone-sensitive prostate cancer: urgent need to minimize the risk of neutropenic fever","volume":"70","author":"Tsao","year":"2016","journal-title":"Eur Urol"},{"key":"2026071706011081300_bib31","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/s0022-5347(17)35251-5","article-title":"Severe reversible neutropenia following treatment of prostate cancer with flutamide","volume":"151","author":"McDonnell","year":"1994","journal-title":"J Urol"},{"key":"2026071706011081300_bib32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.26502\/jcsct.5079204","article-title":"Apalutamide induced neutropenia: an unusual side effect and a literature review","volume":"7","author":"Moria","year":"2023","journal-title":"J Cancer Sci Clin Ther"},{"key":"2026071706011081300_bib33","doi-asserted-by":"publisher","first-page":"e75915","DOI":"10.7759\/cureus.75915","article-title":"Apalutamide: a cause of neutropenic sepsis","volume":"16","author":"Ali","year":"2024","journal-title":"Cureus"},{"key":"2026071706011081300_bib34","doi-asserted-by":"publisher","first-page":"102427","DOI":"10.1016\/j.ctrv.2022.102427","article-title":"Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: a review","volume":"109","author":"Blayney","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2026071706011081300_bib35","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1159\/000345626","article-title":"Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes","volume":"58","author":"Yang","year":"2012","journal-title":"Chemotherapy"},{"key":"2026071706011081300_bib36","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/17474086.2022.2093712","article-title":"G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review","volume":"15","author":"Campbell","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"2026071706011081300_bib37","doi-asserted-by":"publisher","first-page":"436","DOI":"10.6004\/jnccn.2022.0026","article-title":"NCCN Guidelines\u00ae Insights: hematopoietic growth factors, version 1.2022","volume":"20","author":"Griffiths","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2026071706011081300_bib38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0770\/3807049\/crc-25-0770.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1714\/3811516\/crc-25-0770.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1714\/3811516\/crc-25-0770.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:01:21Z","timestamp":1784282481000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/7\/1714\/786600\/Chemotherapy-Induced-Neutropenia-in-Palestinian"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0770","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.33016868","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8601068","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}